Élan

Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Growth, Associated, Horizon Therapeutics, Executive, Patient, Business development, Acquisition, Élan, Inflammation, University College Cork, Commerce, Perrigo, Investment, Corporate development, Autoimmunity, Management

“This newly created position reflects the important inflection point at which we at Ardelyx find ourselves: Envisioning and building our future following the successful launch of two first-in-class medicines within the past two years,” said Mike Raab, president and chief executive officer of Ardelyx.

Key Points: 
  • “This newly created position reflects the important inflection point at which we at Ardelyx find ourselves: Envisioning and building our future following the successful launch of two first-in-class medicines within the past two years,” said Mike Raab, president and chief executive officer of Ardelyx.
  • “It is a pleasure to welcome Mike at this critical period of our growth.
  • His experience and expertise defining and advancing corporate strategies along with his proven track record of delivering value-accretive collaborations and transactions strengthen our leadership team and position us for success.
  • Mr. Kelliher began his career in banking, public accounting and corporate finance and holds a Bachelor of Commerce degree from the University College Cork (Ireland).

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Retrieved on: 
Wednesday, February 21, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Therapy, Pfizer, Gilead Sciences, Multimedia, B.A, University, Sofinnova, Annual general meeting, PLC, Chairperson, Élan, Hyperion, Patient, Novartis, Intercept Pharmaceuticals, Horizon Therapeutics, Chair, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240221419945/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240221419945/en/
    Upon election by the shareholders at Prothena’s Annual General Meeting later this year, the Board intends to appoint Mr. Welch as Chair of the Board.
  • Dr. Ekman will step down as Chair and continue to serve on the board as Chair Emeritus, following the anticipated appointment of Mr. Welch.
  • The entire Prothena Board expresses their sincere gratitude for Dr. Ekman’s valuable service as Chair.
  • Dr. Harfstrand has been a director since 2015 and the entire Prothena Board acknowledges and appreciates his positive impact during his service.

Vanqua Bio Advances Clinical Candidate for Parkinson’s Disease, Expands Leadership Team to Support Further Development

Retrieved on: 
Tuesday, December 12, 2023
Lysosome, Protein, Immune system, Élan, Recycling, Research, Hope, Bristol Myers Squibb, Health, Movement disorder, Doctor of Philosophy, Human, Alector, Glucocerebrosidase, PD, GLP, Glycogen storage disease, Retina, CNS, Biomarker, Regeneron Pharmaceuticals, Growth, Cell, MPH, Patient, Safety, Alpha-synuclein, Neuron, Pharmaceutical industry

Mutations in GBA1 are the most common genetic risk factor for PD, representing approximately 10% of patients with PD worldwide.

Key Points: 
  • Mutations in GBA1 are the most common genetic risk factor for PD, representing approximately 10% of patients with PD worldwide.
  • His research activities have encompassed efforts to develop novel clinical outcome measures and biomarkers, including digital health technologies for clinical trials.
  • As Chief Development Officer, Mr. Siddiqui will drive the progression of Vanqua Bio’s programs through clinical development.
  • Previously, he served as head of clinical development operations at Alector, a biotech company working on leveraging the immune system to discover cures for neurodegenerative diseases.

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

Retrieved on: 
Wednesday, September 6, 2023
Linda, Business development, Duchenne muscular dystrophy, University College Cork, Horizon Therapeutics, Biotechnology, Exosome, Business, Strategic planning, M&A, Patient, Investment, SAN, MUSCULAR, Élan, Associated, Perrigo, Therapy, Horizon, Autoimmunity, Commerce, Inflammation, Pharmaceutical industry, Management

SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately.

Key Points: 
  • SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that the Company has appointed Michael Kelliher to its Board of Directors, effective immediately.
  • Mr. Kelliher, Group Vice President of M&A and Business Development at Horizon Therapeutics, brings to Capricor extensive expertise in business development, strategy, finance and operational leadership across the life sciences industry.
  • “It is a pleasure to welcome Mike to our Board of Directors, who has an extraordinary biopharmaceutical expertise and a strong track record of enhancing success across key business functions,” said Linda Marbán, Ph.D., Capricor’s Chief Executive Officer.
  • Mr. Kelliher joined Horizon in 2014 and led an aggressive growth and expansion agenda through acquisitions, development collaborations and other transactions.

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

Retrieved on: 
Thursday, January 12, 2023
University of Bedfordshire, Development, Executive, Élan, University, Doctor of Philosophy, Third Point Management, City University, IPO, Inflammation, Knowledge, Psoriasis, Ulcerative colitis, Research and development, Marketing, Economics, Growth, Patient, Genentech, PIPE, Cranfield University, Pfizer, Chemistry, Ionis Pharmaceuticals, MBA, Chicago (franchise), Amylin Pharmaceuticals, Pharmaceutical industry, Management, Biotechnology, Research, Ionis, Science

Dr. Allison Hulme currently serves as Chief Executive Officer, President and a board member of Aeovian Pharmaceuticals.

Key Points: 
  • Dr. Allison Hulme currently serves as Chief Executive Officer, President and a board member of Aeovian Pharmaceuticals.
  • Prior to this, she served as Chief Operating Officer, Head of Research and Development and a board member at Sophiris Bio.
  • Ms. Onaiza Cadoret-Manier currently serves as Executive Vice President, Chief Global Product Strategy and Operations officer at Ionis Pharmaceuticals.
  • “Allison and Onaiza’s deep industry experience and commercialization expertise will be an invaluable addition to our board of directors.

CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan

Retrieved on: 
Monday, November 21, 2022
Growth, CFO, Diagnosis, Financial management, Nature, Science, Food, Physician, Instability, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Neurology, Legislation, IPO, Mass meeting, Epilepsy Phenome/Genome Project, Élan, CLIA, Epigenomics, Security (finance), Neurodegeneration, Metabolomics, Supervisory board, KPMG, Precision medicine, Risk, Audit committee, ISO, CAP, Drug discovery, Property management, Pharmaceutical industry, Proteomics

Ms. Sheahan will serve as a member ad interim of the Companys Supervisory Board starting December 1, 2022.

Key Points: 
  • Ms. Sheahan will serve as a member ad interim of the Companys Supervisory Board starting December 1, 2022.
  • It is also planned that Ms. Sheahan will assume the role of Chair of the Audit Committee.
  • Ms. Sheahan currently serves as CFO of Avillion LLP, a private equity-backed life sciences company focused on the co-development and financing of pharmaceutical products.
  • We are very pleased to welcome Ms. Sheahan as a new member of the Supervisory Board, stated Peer Schatz, Chairman of the Supervisory Board of CENTOGENE.

Verge Genomics Appoints John Applegate as Chief Financial Officer

Retrieved on: 
Monday, October 17, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Culture, Science, Rituximab, Verge, Natalizumab, Drug development, MBA, Genentech, Program, ALS, Biogen, Multimedia, Artificial intelligence, Technology, Applegate, Probability, Drug discovery, AI, CEO, Genomics, Élan, Harvard Business School, Pharmaceutical industry, Management, Economics, Northwestern University, PIKFYVE

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that John Applegate will join the company as Chief Financial Officer.

Key Points: 
  • Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that John Applegate will join the company as Chief Financial Officer.
  • View the full release here: https://www.businesswire.com/news/home/20221017005186/en/
    Verge Genomics Appoints John Applegate as Chief Financial Officer (Photo: Business Wire)
    Applegate joins the company from Valo Health, an AI-powered drug discovery company, where he was a member of the founding leadership team and helped grow the company from seed stage to a valuation greater than $1B.
  • Truly transforming drug discovery requires innovation not only on the science and technology, but also on financial strategy and culture, said Alice Zhang, CEO and co-founder of Verge Genomics.
  • Applegate joins Verge after 24 years of finance leadership in both the biotech and technology industries.

Travere Therapeutics Announces Plan for Chief Financial Officer Transition

Retrieved on: 
Wednesday, April 20, 2022
Patent, Williams College, Board, CFA, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Élan, NASDAQ, Xavier University, Annual report, Life, Caregiver, CPA, Private Securities Litigation Reform Act, GLOBE, CFO, Patient, SAN, Growth, Â, Company, Corporate communication, Safety, Genta (company), Disease, Industry, Risk, Business, Therapy, Management, Pharmaceutical industry, Anthony Travers

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief financial officer Laura Clague, CPA, will retire after serving in this role for the past seven years. Ms. Clague will step down from the CFO position in August 2022 and will remain employed by the Company in an advisory capacity into 2023 to facilitate a smooth transition. Chris Cline, CFA, the Company’s current senior vice president of investor relations and corporate communications and a member of the senior leadership team, has been named Ms. Clague’s successor as chief financial officer, to be effective in August 2022.

Key Points: 
  • Chris Cline, Travere SVP of Investor Relations & Corporate Communications, to assume position of chief financial officer in August 2022
    SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief financial officer Laura Clague, CPA, will retire after serving in this role for the past seven years.
  • On behalf of the Board and our Travere employees, I want to thank Laura for her unwavering dedication to our mission and for her many contributions over the past seven years to help establish Travere as a leader in the rare disease community, said Eric Dube, Ph.D. president and chief executive officer of Travere Therapeutics.
  • Mr. Cline brings more than 15 years of industry experience in investor relations, corporate communications, and financial strategy, planning and analysis to the chief financial officer position.
  • Prior to Travere, Mr. Cline was a member of the global investor relations group at Elan Corporation, plc, and the financial planning and analysis group at Phase Forward.

LetGetChecked Appoints Nigel Clerkin as Chief Financial Officer

Retrieved on: 
Thursday, March 24, 2022
Health, Other Health, Élan, Health, EU, CEO, CFO, Â, Industry, Awareness, UDG Healthcare, ConvaTec, United Kingdom, Growth, Pharmaceutical industry, Management

LetsGetChecked, a global healthcare solutions company, announced today that it has appointed Nigel Clerkin as Chief Financial Officer, effective immediately.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company, announced today that it has appointed Nigel Clerkin as Chief Financial Officer, effective immediately.
  • In his new role, Clerkin will be responsible for all aspects of the companys financial strategy and objectives.
  • On behalf of our entire team, Im thrilled to welcome industry veteran Nigel Clerkin to LetsGetChecked, said Peter Foley, Founder and CEO of LetsGetChecked.
  • I am honored to join LetsGetChecked, a company that has the potential for significant growth for many years to come, said Nigel Clerkin, CFO.

ShouTi Strengthens Board With Appointment of Daniel G. Welch as Chairman

Retrieved on: 
Thursday, January 20, 2022
Biotechnology, Health, Science, Other Science, Pharmaceutical, Patient, NUVB, LinkedIn, R, Biotechnology, General manager, NYSE, NASDAQ, CEO, Emtricitabine, Roche, University of North Carolina School of the Arts, Worldwide, Industry, Therapy, Ultragenyx, B.A, The Shouty Track, Computational chemistry, Gilead, Élan, Biopharmaceutical, VC, University, Acquisition, Management, Pharmaceutical industry, Sanofi

ShouTi Inc ., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced that Daniel Welch has been named Chairman of the companys board of directors.

Key Points: 
  • ShouTi Inc ., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced that Daniel Welch has been named Chairman of the companys board of directors.
  • "It is a true privilege to welcome Dan to ShouTi as Chairman of our board, said Raymond Stevens, Ph.D., Chief Executive Officer, ShouTi.
  • He was Chairman, President and CEO of InterMune until its $8.3 billion acquisition by Roche in 2014.
  • Mr. Welch presently serves as Chairman of Ultragenyx Pharmaceutical (NASDAQ: RARE), Chairman of Nuvation Bio (NYSE: NUVB), Executive Chairman of Levo Therapeutics, Executive Chairman of InCarda Therapeutics, and Director of Seagen (NASDAQ: SGEN).